TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06391840: Phase 2/3 Multicenter Study of Revumenib in Combination With Venetoclax and Azacitidine in Frontline NPM1-Mutated or KMT2A-Rearranged AML

Sponsor: Syndax Pharmaceuticals, Inc. · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 185 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT06391840 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06391840 Rescue Dossier →